Patents Assigned to Progenra Inc.
  • Azole compounds as ubiquitin-specific protease USP7 inhibitors
    Patent number: 11273154
    Abstract: Method and compounds for treating cancer by, for example, modulating immune system activity, are provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 15, 2022
    Assignee: PROGENRA, INC.
    Inventors: Hui Wang, Jian Wu, Suresh Kumar Kizhakkethil-George, Feng Wang, Joseph Weinstock
  • AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS
    Publication number: 20200016140
    Abstract: Method and compounds for treating cancer by, for example, modulating immune system activity, are provided.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 16, 2020
    Applicant: Progenra, Inc.
    Inventors: Hui WANG, Jian WU, Suresh Kumar KIZHAKKETHIL-GEORGE, Feng WANG, Joseph WEINSTOCK
  • Covalent irreversible inhibitors of USP7 as anti-cancer agents
    Patent number: 10292973
    Abstract: Compounds and pharmaceutical compositions for treating cancer by, for example, modulating immune system activity, are provided.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 21, 2019
    Assignee: PROGENRA, Inc.
    Inventors: Joseph Weinstock, Jian Wu, Suresh Kumar Kizhakkethil-George, Feng Wang, Matthew P. Kodrasov, Saket Agarwal
  • Methods of treating cancer through the inhibition of USP7 and immune system modulation
    Patent number: 9717717
    Abstract: Methods and compounds for treating cancer by, for example, modulating immune system activity, are provided.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: August 1, 2017
    Assignees: Progenra, Inc., The Children's Hospital of Philadelphia
    Inventors: Joseph Weinstock, Jian Wu, Suresh Kumar Kizhakkethil-George, Feng Wang, Matthew P. Kodrasov, Saket Agarwal, Wayne W. Hancock
  • Methods and compositions for enhanced protein expression and purification
    Patent number: 8691958
    Abstract: Methods for enhancing expression levels, secretion, and purification of heterologous fusion proteins in a host cell are disclosed.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: April 8, 2014
    Assignees: Progenra, Inc., Lifesensors, Inc.
    Inventors: Tauseef R. Butt, Tadas Panavas, Amolkumar Karwa, Raymond J. Peroutka, Jeffrey G. Marblestone
  • Di- and Poly-Ubiquitin Deubiquitinase Substrates and Uses Thereof
    Publication number: 20140072992
    Abstract: Methods for detection of the activity of proteolytic enzymes, particularly isopeptidases, are disclosed.
    Type: Application
    Filed: August 26, 2013
    Publication date: March 13, 2014
    Applicants: Progenra, Inc., Lifesensors, Inc.
    Inventors: Dattananda Chelur, Michael Eddins, Craig Leach, Steven J. Orcutt, Raymond J. Peroutka, James Strickler, Yilin Yan, Kathryn Longenecker
  • Di- and poly-ubiquitin deubiquitinase substrates and uses thereof
    Patent number: 8518660
    Abstract: Methods for detection of the activity of proteolytic enzymes, particularly isopeptidases, are disclosed.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 27, 2013
    Assignees: Lifesensors, Inc., Progenra, Inc.
    Inventors: Dattananda Chelur, Michael Eddins, Craig Leach, Steven J. Orcutt, Raymond J. Peroutka, James Strickler, Yilin Yan, Kathryn Longenecker
  • Method for assessing proteolytic enzyme activity using ubiquitin fusion substrate
    Patent number: 7842460
    Abstract: Methods and kits for assessing proteolytic enzyme activity and a modulator's effect thereof employ a Ubiquitin or Ubiquitin-like Protein and a signal producing structure. The corresponding fusion polynucleotide is employed for production of transgenic cells, plants and animals that may be produced by stably transfection, optionally transforming the cell, plant or animal with a Ubiquitin-, UBL- or their C-terminal binding functional fragment-Reporter fusion polynucleotide. A method of diagnosing a disease or condition, comprises contacting or administering a sample obtained from a subject suspected of being afflicted with the disease or condition with the cell, plant or animal, detecting any signal produced by the reporter in the presence of the sample and comparing the signal to controls for 0% and 100% signals.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: November 30, 2010
    Assignee: Progenra Inc.
    Inventors: Tauseef R. Butt, Alejandro Bernal